All In Biotech

Drug Trial Radar · NCT03682536

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions

Last checked: Nov 20, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 363 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

363

Actual

Start

Jan 2, 2019

Primary completion

Mar 31, 2023

Study completion Sep 28, 2027

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
First posted
Sep 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at least 1.5 g/dL in participants with anemia due to revised international prognostic scoring system (IPSS-R) very low, low, or intermediate risk myelodysplastic syndromes (MDS) who require RBC transfusions and have never been exposed to erythropoiesis stimulating agent (ESA).

Conditions

  • Myelodysplastic Syndromes

Interventions

  • LuspaterceptDrug

    Specified dose on specified days

  • Epoetin alfaDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Red Blood Cell Transfusion Independence (RBC-TI) for 12 Weeks (84 Days) With a Mean Hemoglobin Increase ≥ 1.5 g/dLTime frame: Week 1 through Week 24

Locations

226 sites in 26 countries. Site status is shown where the registry gives one.

  • Local Institution - 107

    Berkeley, California

  • Local Institution - 115

    San Diego, California

  • Local Institution - 101

    Whittier, California

  • Local Institution - 104

    New Haven, Connecticut

  • Local Institution - 136

    Washington D.C., District of Columbia

  • Local Institution - 119

    Hudson, Florida

  • Local Institution - 120

    St. Petersburg, Florida

  • Local Institution - 122

    Tallahassee, Florida

  • Local Institution - 108

    Tampa, Florida

  • Local Institution - 118

    West Palm Beach, Florida

  • Local Institution - 102

    Paducah, Kentucky

  • Local Institution - 123

    Bethesda, Maryland

  • Local Institution - 117

    Kansas City, Missouri

  • Local Institution - 134

    East Brunswick, New Jersey

  • Local Institution - 113

    Hackensack, New Jersey

  • Local Institution - 105

    Greenville, North Carolina

  • Local Institution - 131

    Portland, Oregon

  • Univ of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Local Institution - 111

    Rock Hill, South Carolina

  • Tennessee Oncology

    Nashville, Tennessee

  • Baylor University Medical Center

    Dallas, Texas

  • Local Institution - 109

    Houston, Texas

  • Local Institution - 114

    Salt Lake City, Utah

  • Local Institution - 132

    Charlottesville, Virginia

  • Local Institution - 127

    Chesapeake, Virginia

  • Local Institution - 212

    Randwick, Australia

  • Local Institution - 206

    Albury, New South Wales, Australia

  • Local Institution - 213

    Blacktown, New South Wales, Australia

  • Local Institution - 200

    Concord, New South Wales, Australia

  • Local Institution - 215

    Kogarah, New South Wales, Australia

  • Local Institution - 211

    Nowra, New South Wales, Australia

  • Local Institution - 210

    Waratah, New South Wales, Australia

  • Local Institution - 207

    Wollongong, New South Wales, Australia

  • Local Institution - 208

    Auchenflower, Queensland, Australia

  • Local Institution - 202

    Adelaide, South Australia, Australia

  • Local Institution - 204

    Clayton, Victoria, Australia

  • Local Institution - 203

    Malvern, Victoria, Australia

  • Local Institution - 209

    Melbourne, Victoria, Australia

  • Local Institution - 205

    West Perth, Western Australia, Australia

  • Local Institution - 442

    Linz, Austria

Showing 40 of 226 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.